XORTX Therapeutics (XRTX) EBITDA (2020 - 2026)
XORTX Therapeutics' (XRTX) quarterly EBITDA came in at -$823297.0 in Q1 2026, up 14.55% YoY from -$718738.4 in Q1 2025, and up 84.25% on a QoQ basis from -$5.2 million in Q4 2025.
XORTX Therapeutics (XRTX) EBITDA (2020 - 2026) Analysis & Trends
XORTX Therapeutics (XRTX) has 7 years of EBITDA data on file, last reported at -$823297.0 in Q1 2026.
- Quarterly EBITDA rose 14.55% year-over-year to -$823297.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.7 million (down 140.12% YoY) and the FY2025 annual result came in at -$2.6 million, up 18.08% from the prior year.
- EBITDA grew to -$823297.0 in Q1 2026, from -$5.2 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $2.9 million in Q4 2023 to a low of -$5.2 million in Q4 2025.
- A 5-year average of -$1.1 million and a median of -$963456.0 in 2025 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2023 — EBITDA jumped 289.84% — and 2025, when it plunged 3736.45%.
- Tracing XRTX's EBITDA over 5 years: stood at -$1.5 million in 2022, then jumped by 289.84% to $2.9 million in 2023, then plunged by 95.05% to $143709.0 in 2024, then sank by 3736.45% to -$5.2 million in 2025, then surged by 84.25% to -$823297.0 in 2026.
- The last three EBITDA figures came in at -$823297.0 (Q1 2026), -$5.2 million (Q4 2025), and -$716197.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | XORTX Therapeutics | 2.78 Mn | 2.78 Mn | - | -823,297.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -823,297.00 |
| Dec 31, 2025 | -5.23 Mn |
| Sep 30, 2025 | -716,197.00 |
| Jun 30, 2025 | -889,945.00 |
| Mar 31, 2025 | -963,456.00 |
| Dec 31, 2024 | 143,709.00 |
| Sep 30, 2024 | -874,749.00 |
| Jun 30, 2024 | -1.49 Mn |
| Mar 31, 2024 | -1.09 Mn |
| Dec 31, 2023 | 2.90 Mn |
| Sep 30, 2023 | -1.39 Mn |
| Jun 30, 2023 | -1.26 Mn |
| Mar 31, 2023 | -1.36 Mn |
| Dec 31, 2022 | -1.53 Mn |
| Sep 30, 2022 | -882,437.52 |
| Jun 30, 2022 | -959,894.13 |
| Mar 31, 2022 | -2.87 Mn |
| Dec 31, 2021 | 306,879.85 |
| Sep 30, 2021 | -322,734.34 |
| Jun 30, 2021 | -704,604.01 |